EvokAI Creative Labs

EvokAI Creative Labs EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EvokAI Creative Labs (OKAI.V) as of Oct 21, 2026 is -1.65 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -333,100.00 USD — a change of 395.47% (lower).

EBITDA

-1.65 MUSD

YoY

395.47%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EvokAI Creative Labs is 2023 -1.65 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EvokAI Creative Labs was 2022 -333,100.00 USD. It decreases by 395.47% lower compared to the previous year.

The EvokAI Creative Labs EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-88,600.00 USD
Jan 1, 2021
-60,700.00 USD
Jan 1, 2022
-333,100.00 USD
Jan 1, 2023
-1.65 M USD
The EvokAI Creative Labs EBITDA history
YEAREBITDAYoY
-1.65 MUSD+395.47%
-333,100.00USD+448.76%
-60,700.00USD-31.49%
-88,600.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EvokAI Creative Labs Stock analysis

What does EvokAI Creative Labs do? EvokAI Creative Labs Inc develops AI algorithms for healthcare, deploying machine learning to search medical data and uncover insights for improved health outcomes. The company offers its AI solutions across the healthcare system, targeting hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, medical professionals, patients, and healthy individuals. Its divisions include EvokAI Simulators, EvokAI Sensors, EvokAI Neurotrainer, and EvokAI Medical, with EvokAI Simulators combining cognitive neuroscience, virtual reality, and AI to assess cognitive performance and spatial perception. The company generates revenue by providing AI-driven insights and tools to healthcare stakeholders, including pharmaceutical companies and research institutions, for drug development, clinical decisions, and disease prevention. EvokAI Simulators specifically serves medical professionals and patients seeking cognitive assessments through virtual reality and AI integration. EvokAI Medical supports healthcare providers in delivering accurate diagnoses and improving patient experiences. EvokAI Sensors and EvokAI Neurotrainer cater to diverse healthcare segments, from early disease detection to enhancing cognitive training. The company's focus on preventing and early detecting diseases aligns with the needs of aging populations and health-conscious individuals, driving demand for its AI-powered solutions across the healthcare ecosystem. EvokAI Creative Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EvokAI Creative Labs stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EvokAI Creative Labs is -1.65 M USD in 2023.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EvokAI Creative Labs changed from -333,100.00 USD to -1.65 M USD, representing a 395.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) EvokAI Creative Labs since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EvokAI Creative Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — EvokAI Creative Labs

All Key Metrics — EvokAI Creative Labs